Companies › Evommune
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Immunology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EVO756 | – | Phase 2 | Atopic Dermatitis; Migraine | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07150845 | EVO756 | Phase 2 | Atopic Dermatitis | Immunology | Jul 2026 |
| NCT07616128 | EVO756 | Phase 2 | Migraine | Neurology | Oct 2027 |
Cash and short-term investments of $201m on 2026-06-30; operating cash outflow about $97m a year; runway about 25 months at that burn, to Jul 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Aclaris Therapeutics Coya Therapeutics Cognition Therapeutics DiaMedica Therapeutics Palisade Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.